What we know so far
While cabergoline (and other dopamine agonists) are not the only drugs that can inhibit angiogenesis, the Boston and Brigham researchers believe that cabergoline has a better safety profile compared to other drugs with the same effect. They are currently enrolling more women in a new clinical trial to attempt to increase their sample size and glean more information about the potential benefits of cabergoline for endometriosis-related pain (this time, compared to a placebo).
With a larger sample size, the researchers can also measure how (or if) cabergoline helps reduce other symptoms of endometriosis, like infertility or irregular bleeding, plus whether cabergoline shrinks endometriosis lesions or prevents or slows existing lesion growth. A tiny 2011 study of just nine women found that another dopamine agonist, quinagolide, decreased endo lesions by 69.5% over the course of 20 weeks [7]. Might cabergoline do the same?